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Tacrolimus (FK 506)-A New Therapeutic 
Agent for Severe Recalcitrant Psoriasis 
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• Background.-Psoriasis, a disease of unknown etiology, 
is in some patients severe, extremely debilitating, and unre-
sponsive to conventional therapies, including UV-B, oral 
psoralen with long-wave UV radiation in the A range (PUVA), 
oral retinoids, and methotrexate. We report the results from 
our study of seven patients with refractory psoriasis who 
were treated with the new immunosuppressive drug, tacroll-
mus (FK 506). 
Observstions.-AII seven patients showed a dramatic 
resolution of psoriasis that remained in remission as long as 
they received full-dose therapy. Serial skin biopsy speci-
mens demonstrated a rapid disappearance of the inflamma-
tory infiltrate and a slower resolution of the epidermal 
changes. Tacrolimus was well tolerated during the 5.5 to 14 
months of observation. Side effects, including nephrotoxic-
ity and hypertension, were controlled by appropriate modi-
fication of drug dosage. 
Conclusions.-Tacrolimus, a new immunosuppressive 
agent, is effective in treating patients with severe recalcitrant 
psoriasis. The mechanism of Its action in psoriasiS is 
unknown, but it may be related to Its ability to modulate im-
mune function. Further studies will establish criteria for pa-
tient selection and drug dosage, to maximize efficacy of this 
agent in psoriaSiS, while minimizing its toxicity. 
(Arch Dermatol. 1992;128:781-785) 
Psoriasis. a common heritable disease that affects the 
skin, the joints, or both, has many characteristics of 
an immunologically mediated disease. Included among 
these characteristics are a variable HLA association, 
lymphocytic infiltration of skin lesions. and evidence of 
cytokine actiyity or increased expression of new anti-
gens during exacerbations. I.:! Circumstantial eyjdence 
for an immune etiology is the striking remission of pso-
riatic lesions that can be achieved with cyclosporine/" 
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Table 1.-Clinical Features' 
No.1 Trans- Disease 
Age, yl plant Duration. y Previous 
Sex Type (Psoriasis) Therapy Arthritis 
Transplant reCipients 
1/36/F Heart 12 Topical steroids: -
UV-B+tar 
2t/40/M liver 22 UV-B+tar: methotrexate + 
3!33/F liver 25 PUVA: topical sterOids: -
Intraleslonal steroids: 
methotrexate 
--
4/28/F liver 5 Topical sterOids: -
systemic sterOids 
Psoriasis on Iy 
5i49/F - 6 PUVA. UV·B: topical + 
sterOids: etrellnate 
6/30/M - 6 UV-B+tar: topical + 
sterOids: gold 
intramuscularly: 
methotrexate 
7/32JF - 9 UV-B+tar: topical + 
steroids: methotrexate 
'PUVA indicates oral psoralen With long-wave UV radiation in the 
A range (320 to 400 mm): UV-B. ultraviolet B (280 to 320 mm). Minus 
indicates absent: plus. present. 
tEnd-stage ilver disease was secondary to methotrexate therapy. 
an immunosuppressive drug whose use for this purpose 
has been limited its by nephrotoxicity, hypertension, 
and other dose-related side effects. We report our expe-
rience with tacrolimus (FK 506), another immunosup-
pressive drug that is unrelated chemically to cyclospo-
rine but also. inhibits helper T -lymphocyte activation and 
the syntheSIS and expression of cytokinesKfiK~ Encourag-
ing results with tacrolimus have been reported in trials 
of whole organ transplantation."'1II 
PATIENTS AND METHODS 
Clinical features are summarized in Table 1. Amelioration 
of psoriasis in four patients was incidental to the primary ob-
jective, preventing organ rejection of heart (one patient) or 
Ii ver transplantation (three patients). The liwr disease in one 
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Table 2.-Adverse Reaction Surveillance to June 6 
Petlent 
I I 
1 2 3 4 5 6 7 
Date tacrolimus 
7/13190 8/8190 5/24/90 7/16/90 8/27/90 therapy started 2114190 6/30190 
FK doses. mglkg per day 
At start 0.27 0.30 0.35 0.25 0.28 0.29 0.2 
3 mo 0.33 0.20 0.40 0.18 0.10 0.30 0.32 
Now 0.21 0.13 0.29 0.18 0.30 0.40 0.32 
FK plasma. nglmL 
1 wk 1.4 2.5 4.3 3.4 1.1 2.0 0.8 
3mo 1.5 1.0 0.9 1.2 0.4 0.4 0.9 
Now 1.1 0.8 0.5 1.4 1.3 0.7 1.2 
Steroid dose. mgld 
At start 20 20 20 20 0 0 0 
3 mo 10 0 10 0 0 0 0 
Now 0 0 15 0 0 0 0 
Creatinine. ILmollL 
At start 62 53 53 53 88 80 71 
3 mo 141 150 150 106 106 133 150 
Now 176 159 159 97 159 159 124 
Serum urea nitrogen, 
mmol/L 
At start 2.5 3.6 
3 mo 15.7 7.1 
Now 9.3 11.8 
Fasting blood glucose. 
mmol/L 
At start 4.7 4.7 
3 mo 4.9 5.3 
Now 5.7 4.0 
Uric acid, ILmoi/L 
At start 636 369 
3 mo 565 434 
Now 494 571 
MagneSium, ILmoi/L 
At start 0.86 0.58 
3 mo 0.49 0.49 
Now 0.58 0.62 
Potassium, mmol/L 
At start 4.1 3.2 
3 mo 4.1 4.1 
Now 4.6 4.8 
._. 
Cholesterol. ILmoi/L 
At start 4.3 1.7 
. 
3 mo 5.3 3.9 
Now 4.7 4.7 
of the latter patient:; was caused by high-dose methotrexate 
:;odium treatment fol' psoriasis during a 2-year period. The 
other three patient:; had ~eyDere recalcitrant p:;orimii:; that 
had resisted the therapies listed in Table 1. 
Psoriasis Evaluation 
The :;everity of psoriasi:; wa:; quantitated using the Psori-
asis Area and Severity Index.:··11 The assessment is per-
formed by measuring the extent of :;kin involvement and the 
amount of erythema. infiltration. and desquamation using a 
scale of 0 to 4 (0 indicates none: 1. slight: 2. moderate: a. se-
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4.3 2.5 2.1 3.2 3.6 
13.2 9.6 2.5 7.5 10.4 
12.8 10.4 10.4 7.1 6.8 
5.7 5.1 5.9 5.1 4.4 
6.7 5.4 5.7 4.3 5.8 
5.0 5.5 5.5 5.5 5.2 
214 280 517 321 357 
428 464 399 297 410 
476 458 476 303 428 
0.66 0.62 0.58 0.62 0.58 
0.66 0.74 0.58 
... - .. -K------~ 
0.49 0.49 
... 0.70 0.45 0.45 0.49 
3.5 3.9 4.3 4.8 4.5 
3.3 5.2 3.8 4.8 4.5 
----_._--_. -
4.3 5.2 4.6 5.0 4.1 
_._._-----
._-- ---- ---
6.3 3.3 4.5 4.7 3.5 
5.6 2.9 6.6 3.6 3.6 
5.4 ... 6.1 3.7 36 
\'ere: and -I. \'erv :;e\·ere). Each of the abo\'e clinical :,iI..'l1:' \\'a,; 
given an appropriate :'core and a tompo,:ite additive ~umhE>r 
obtained that repre:Ient~ the m~oria:;iI; Area and peyDerit~· In-
dex. In the three patients whose primary dia!£l1o:;i:; wa,; p:,o-
riasis. biopsy specimens were obtained before institutin~ 
treatment. 2 weeks later. and when they were clinically free 
of lesions. 
Dose Control 
Oral tacrolimus therapy was started at 0.15 mgikg. t\\;ce 
daily. in the patients who did not receive organ tran~plants 
Tacrolimus-Jegasothy et al 
t:\,.,;""",;;; ~ ~K '.'.: ":. - -. .: . 
.. ~ . .:" 
Fig 1.-Lett. Generalized erythrodermic psoriasis in patient 5 before tacrolimus (FK 506) 
treatment: right. complete resolution after 3 weeks of tacrolimus treatment. 
... 
_ ........ 
,. 
and the do~age was adjusted. as necessary, according to tac-
rolimus plasma levels. Plasma levels were measured at a 12-
hour trough using an enzyme-linked immunoassayKl~ Similar 
dosage adjustments were made when clinical evidence indi-
cated incomplete disease control or toxic reactions. No other 
antipsoriatic therapy was used. The transplant recipients 
were initially administered intravenous doses of 0.075 or 0.10 
mgfkg tacroiimus per day and converted to therapy with oral 
medications when they could begin oral feeding. Patients who 
had received transplants also received prednispne initially, 
doses of which were tapered to levels shown in Table 2 at the 
time of their last follow-up \'isit. 
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Fig 2.-Left. Histopathologic findings of patient in Fig 1 show-
ing typical changes of pSOriasis before tacrolimus (FK 506) 
treatment; right. 2 weeks later. Note persistence of epidermal 
acanthosis. but almost complete resolution of dermal and 
epidermal inflammation (hematoxylin-eosin. x 1 00). 
Side Effect Surveillance 
Extensive medical examinations. including complete neu-
rologic assessments. were performed repeatedly. Results of 
renal function tests and levels of serum cholesterol. uric acid. 
blood glucose. serum magnesium. and other electrolytes were 
carefully monitored. Development of high blood pressure (if 
present) was quantitated by the number of antihypertensive 
drugs required to maintain a normotensi\'e state. Hyper-
kalemia. if it occurred, was treated with the mineralocorti-
coid. fludrocortisone acetate. Hypomagnesemia seen in some 
patients did not require correction. 
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Table 3.-Psoriasis End Points in Three 
Nontransplant Patients 
Week 
Clinical Base- I I 
(PAS'- Scores) line 2 4 6 Now 
Patient 
5 67.5 27 2.8 0 0 
6 43.4 5.7 0 0 0 
7 68.4 34.2 9.8 0 0 
Histopathologlct 
Epidermal 
acanthosis +++ +++ + + -
Munro/Micro-
abscesses +++ - - - -
Active dermal 
inflammation ++++ + - - -
·PASI indicates Psoriasis Area and Severity Index. 
tOne plus indicates minimal: three pluses. moderately severe; four 
pluses. severe: and minus. absent. 
RESULTS 
Effect on Psoriasis 
There was a marked reduction in erythema and scale 
in all seven patients at the end of 1 week and complete 
clinical remission within 4 weeks (Fig 1). The remis-
sions ha\'e been sustained in all patients. Our follow-up 
periods range from 5.5 to 14 months. Interpretation of 
the beneficial effect of tacrolimus was straightforward 
in the three patients whose primary diagnosis was 
psoriasis (Table 3) because they were not given sys-
temic corticosteroids or other antipsoriatic medica-
tions. Improvement of psoriatic arthritis, with reduc-
tion in stiffness, pain on movement. and swelling, also 
occurred simultaneously in all three patients. Serial 
skin biopsy specimens obtained from the active plaques 
of psoriasis demonstrated a rapid disappearance of the 
inflammatory infiltrate in the dermis and the neutro-
phib in the stratum corneum (Fig 2). The h~Dperkera­
tosis and epidermal acanthosis took longer to re\'ert to 
normal (Table 3). Efforts to reduce tacrolimus dosage 
in these three patients resulted in the rapid reappear-
ance of early psoriatic skin lesions. which promptly re-
solved on returning to the immediately prior dose of 
tacrolimus. 
The foul' patients who had organ transplants re-
cei\'ed systemic prednisone therapy postoperatively. 
but their remission persisted after lowering (patient :~F 
or stopping (patifnt,,; 1. 2. and -!) the corticosteroid 
therapy (Table 2J. Se\'eral months postoperativel~DI 
when there was no evidence of graft dysfunction. the 
liver recipient whose end-stage hepatic disease was 
caused by methotrexate therapy (patient 2) had small 
psoriatic plaques develop neal' the exit ,,;ite of his T 
tube. These psoriatic plaques disappeared \\'ith a minor 
increase in tacrolimus dose. 
Toxicity and Metabolic Changes 
Tacrolimus dosage. plasma levels. and sUl'\'eillance 
measurements were similar in patients who had and did 
not have transplants. Transient trembling, paresthe-
sias. and insomnia not requiring tacrolimus dose 
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changes were noted in three patients. Increases of se-
rum creatinine or serum urea nitrogen levels signaled 
the need for downward dose adjustments. Most pa-
tients required a decrease of 10% to 25% of the total 
dose. Despite careful monitoring of dosage, serum cre-
atinine and serum urea nitrogen levels increased at our 
check points (Table 2). Although generally stable, the 
final levels of these measures were higher in all 
patients when compared -with pretreatment values. 
Three patients had development of arterial hyperten-
sion that was controlled -with single antihypertensive 
drug therapy; one patient who initially required two 
antihypertensive drugs was later normotensive with 
no drugs, and one patient with preexisting hyperten-
sion requiring one drug for control had no change while 
receiving tacrolimus therapy. 
COMMENT 
Tacrolimus caused a complete remission of psoriasis 
in all seven treated patients. Improvement was always 
evident within a few days. In the patients who did not 
have transplants, tacrolimus dose and plasma levels 
needed to maintain remission of psoriasis were in the 
same range as those required to prevent allograft re-
jection. Efforts to reduce the dose of tacrolimus in 
these patients resulted in reactivation of the psoriasis. 
In one liver recipient (patient 2), dose reduction caused 
a minor recurrence of psoriasis without evidence of 
b'Taft rejection. 
Whether the reward of complete control of psoriasis 
will be worth the risk of long-term therapy with this 
powerful drug can be judged only after future studies. 
The first administration of tacrolimus to a human to 
prevent organ rejection occurred only 29 months ago.1i 
Our patients with psoriasis. whose cases are reported 
herein, have been treated with tacrolimus for 5.5 to 14 
months. The results are very encouraging. The only 
potentially serious side effect was nephrotoxicity. In 
patients with psoriasis as their primar~D disease. serum 
creatinine levels increased 27':( to 111 r( (mean, G8,:() 
above baseline early in their course. but later stabilized 
at 66% to 74% Eme~nK G8O/C) above pretreatment levels. 
In the patients with psoriasis who also underwent or-
gan transplantation, serum creatinine le\'els increased 
100% to 200% (mean. 152q) abO\"e baseline. but later 
stabilized at :-\:-)('r to 20W, (mean. l!i(jr() abo\'e pre-
treatment values. Patients \\'ho are candidates for or-
gan transplantation lfsuall~D have some deg1'ee of incip-
ient renal compromise. which may ha \'to, predisposed 
them to greater tacrolimus nephrotoxic reactions, 
Elevations in serum creatinine and serum urea 
nitrogen levels responded to close reduction and 
reached an increased but stable state at the surveil-
lance check points. No patient has had an infection. The 
patients \\ith psoriasis who did not ha\'e transplants 
who were accepted for our study were those who had 
severe. widespread treatment-resistant disease that 
completely ruined their quality of life. Patients v.ith 
less severe disease are not candidates for treatment 
with tacrolimus until further experience regarding the 
severity and long-term effects of nephrotoxic reactions 
are understood. 
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The remarkable efficacy of tacrolimus in psoriasis is 
attributable to its effect on immune modulation. How-
e'-er .. this may not be the sole explanation for its effect. 
I t is knovm that the cytosolic receptors for this drug 
(called "FK binding protein") as well as the distinct 
cyclosporine-binding site (cyclophilin) are part of a 
pre,-ious!y unrecognized class of small molecular 
'\'eight proteins collectively called "immunophilins." 
These proteins are found in the cytoplasm of essentially 
all eukaryotic cells, including those of the skin. from the 
!()\\'est to highest species. including man.I:l The binding 
of these immunophilins with cyclosporine, tacrolimus, 
and presumably other drugs can affect signal trans-
duction in nonimmunologic as well as immunoregula-
tory cells. Thus, an array of metabolic consequences 
could result affecting growth control as has been dem-
onstrated in the liver.14 Growth control in the skin can-
not be excluded as a target of such nonimmunologic ef-
fects. 
This investigation was aided by research grants from the Veter-
ans Administration and project grant DK 29961 from the National 
J nstitutes of Health. Bethesda, Md. 
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Treatment of Painful Diabetic Neuropathy With Topical Capsaicin 
The Capsaicin Study Group. lArch Intern Med. 1991;151:2225-2229) 
In this large multicenter study, 277 patients with cutaneous pain secondary to diabetic 
neuropathy were treated with capsaicin or its vehicle. Those patients who used capsaicin re-
ported better pain relief, as evaluated by both the patient and physician. Although the re-
sults were significant on a statistical basis, the overall improvement was not terribly 
impressive. Nevertheless, at the theoretical level, it is important that cutaneous pain of more 
than the post herpetic type can be modified with topical therapy. 
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